Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b

Noël Emile Célestin Schartz, Suzanne Buder, Hans Sperl, Heike Audring, Ralph Paus, Beate Tebbe, Katharina Krüger, Wolfram Sterry

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Schnitzler's syndrome (SS) is characterized by the association of generalized chronic urticaria, osteocondensation and monoclonal IgM gammopathy. Nonsteroidal anti-inflammatory drugs and systemic steroids are the most promising treatments. In our patient, they were ineffective. By contrast, during the follow-up period of 18 months, interferon α2b therapy (IFN-α) relieved the patient from its urticarial lesions and bone pain. IFN-α was tried to be stopped twice: each time, relapse of urticaria was noticed and, each time, the cutaneous lesions disappeared after IFN-α had been reintroduced. Furthermore, our observation supports the idea of the interleukin (IL)-1-mediated pathogenesis of SS as IFN-α induces high levels of IL-1 receptor antagonists. IFN-α could be an alternative treatment in disabling SS resisting other drugs.

Original languageEnglish (US)
Pages (from-to)54-56
Number of pages3
Issue number1
StatePublished - Dec 1 2002
Externally publishedYes


  • Interferon α
  • Interleukin 1 receptor antagonists
  • Schnitzler's syndrome

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b'. Together they form a unique fingerprint.

Cite this